Swedish Orphan Biovitrum AB (publ) KOL Haemophilia Call (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Alistair David Campbell - RBC Capital Markets, Research Division - Analyst : Yes, one for Dr. Klamroth, please. Basically, I'd love to understand of the patients you're currently treating with factor, what percentage are on prophylaxis versus on demand? And do you think actually the availability of EFA could change that dynamic and you could see more patients moving from on-demand towards prophylaxis? And then I'd also just like to get a sense of how important you think the lack of inhibitor data are so far in terms of the profile you've seen with EFA.

Question: Alistair David Campbell - RBC Capital Markets, Research Division - Analyst : Well, I kind of follow up and trying to understand why so many -- the patients who have stayed on plasma derived, what was led them to stay on plasma-derived and whether that could change now with EFA.

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : I guess I have a few that are kind of all related to each other for DR. Klamroth. And then one for Guido, and I'll just shoot that one across quickly first shot. Do you think that you can get faster launches across Sobi territory than you did with Elocta? And then for DR. Klamroth, I'm just thinking about the profile of ethanol that came out of the trial where it's, I guess, the first to show improved joint health in a prospective pivotal trial and also I guess we have some encouraging quality of life outcomes data from that as well, right? So to what extent -- we also know that mild hemophilia patients will ultimately experience joint damage over the course of their lifetime. So to what extent do you think that joint health is appreciated or sort of the impact of therapies on joint health is appreciated today is if you see -- were you as surprised to see the improvements in pain and joint health in the clinical program here. And I guess thinking about the results in the surgical setting, does that kind of greater freedom to have surgery with fewer complications treatment issues make it more attractive for the elderly patients that are on other older therapies?

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : And then there was just also in terms of the surgical advantages? Is that something that could help to convince elderly people on older products, but it's worth the risk to change or maybe not such a strong factor?

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : We've heard a number of people experts mowing the idea of biweekly dosing rather than once weekly. But I guess, yes, we don't know whether or not the -- is that something that makes sense to you or given the chronic sinusitis is that something that would need to be tested prospectively? What are your thoughts around that?

Question: Luisa Hector - Berenberg - Analyst : I just want to explore a little bit more with Dr. Klamroth about the first patients that are likely to use EFA, just to kind of profile as a patient. And we've touched on various parameters. But I'm just trying to get a sense of very much this will be a switch, will it be switched from the short-acting and severity age, just the kind of color who you think is literally sitting there ready to be the first patients that use EFA. And how will this be decided? How often are you seeing your patients each year? Is this going to be you recommending the switch? Do you expect some of them to be informed and to be requesting that? And then maybe a quick follow-up on -- you talked about the Hemlibra patients using backup Factor VIII. I didn't hear, sorry, but I don't know if you quantified what percentage that might be and whether that is just simply linked to their levels of activity that they would require the backup? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 18, 2023 / 1:00PM, SOBIV.ST - Swedish Orphan Biovitrum AB (publ) KOL Haemophilia Call (Virtual)

Question: Luisa Hector - Berenberg - Analyst : Could I just follow up and see, so that sort of patient who they're not controlled that you may be saying there's too many bleeds and that they have certain issues. I don't know what proportion that might be? Or maybe the question would be what proportion of your patients come in at each visit and they're perfectly happy. Everything is going well, they're complying and you have no concerns, what proportion that would be?